Relmada Therapeutics Inc RLMD

NAS: RLMD | ISIN: US75955J4022   30/04/2025
0,322 USD (+13,48%)
(+13,48%)   30/04/2025

7 augustus 2024 · Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

18 juni 2024 · Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry · Persbericht

10 juni 2024 · Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

3 juni 2024 · Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference · Persbericht

8 mei 2024 · Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results · Persbericht

6 mei 2024 · Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 · Persbericht

19 maart 2024 · Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results · Persbericht

12 maart 2024 · Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 · Persbericht

5 maart 2024 · Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference · Persbericht

4 januari 2024 · Relmada Therapeutics Provides Corporate Update · Persbericht

8 november 2023 · Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results · Persbericht

3 november 2023 · Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 · Persbericht

11 oktober 2023 · Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 · Persbericht

9 oktober 2023 · Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit · Persbericht

6 oktober 2023 · Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress · Persbericht

20 september 2023 · Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder · Persbericht

23 augustus 2023 · Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder · Persbericht

8 augustus 2023 · Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results · Persbericht

1 augustus 2023 · Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 · Persbericht

8 juni 2023 · Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference · Persbericht

Mijn selecties